Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study

Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study

Enoxaparin is indicated for thromboprophylaxis in non-orthopedic surgical patients at a fixed dose of 40 mg daily. According to the US Food and Drug Administration’s enoxaparin prescribing information, this dose exposes low-weight patients (males < 57 kg, females < 45 kg) to a higher risk of b...

Full description

Bibliographic Details
Main Authors: Hakeam A. Hakeam MS Pharm, BCPS, Zainab Al Duhailib MBBS, EDIC, Muhannad Alsemari MBBS, Reem M. Alwaibah PharmD, Madhawi F. Al Shannan PharmD, Munirah Shalhoub PharmD
Format: Article
Language:English
Published: SAGE Publishing 2020-06-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/1076029620931194

Internet

https://doi.org/10.1177/1076029620931194

Similar Items